Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes and obesity, and growing evidence suggests potential benefits in dermatologic disease. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.